Right Turn: The ABCs of IP and CEO

For Canada to thrive, supporting and training our future work force and leaders is crucial. This can happen in a myriad of ways. For a group of Canadian organizations in the biotherapeutics field, this has taken the form of joining together to host training workshops for graduate students and early career researchers.

Last year, the Clinical Translation Education Group (CTEG)* hosted Bench to Bedside for Biotherapeutics (“B3”), a successful one-day workshop that offered an introduction to translating discoveries into the clinic. You can read a summary of last year’s event here, courtesy of Shreya Shukla PhD who attended the event.

CTEG is back with a new workshop for 2018 and it’s not too early to start planning your training opportunities for the next academic year.

For our next outing on September 14, 2018, CTEG will take on new themes. Here’s a hint:

Intellectual property: property (such as an idea, invention, or process) that derives from the work or the mind or intellect; also, an application, right, or registration relating to this. (Merriam-Webster)

Entrepreneurship: the activity of setting up a business or businesses, taking on financial risks in the hope of profit. (Oxford)

Ainslie Little PhD, Director of Intellectual Property at BlueRock Therapeutics, and a leading patent expert in stem cell technologies, is the keynote speaker. She will educate the audience about IP and share her patent strategy for BlueRock.

Other high calibre IP and business experts will also take part. By the close of the workshop, attendees will understand the following:

• What is IP?
• How do you conduct a patent search?
• How do you navigate the IP process with your university’s Tech Transfer Office (TTO)?
• What are the fundamental aspects of entrepreneurship in the context of a biotherapeutic discovery?

For more details about the event, travel awards and to register, click here.

Our workshops are video-taped to assist with learning and recall, and for those not able to attend. Below is what happened last year.

*CTEG is: BioCanRx, CellCAN, CCRM, Ontario Institute for Cancer Research, Ontario Institute for Regenerative Medicine and Stem Cell Network. (The Foundation Fighting Blindness is on hiatus in 2018.)

The following two tabs change content below.

• Bio
• Latest Posts

Stacey Johnson

Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.

Latest posts by Stacey Johnson (see all)

• Right Turn: #pinksocks, diabetes news and other ramblings - June 24, 2025
• Right Turn: Some takeaways from Advanced Therapies Week 2025 - January 31, 2025
• Right Turn: The top 10 most-read blog posts in 2024 - January 2, 2025